SLI
2.129,45
PKT
-59,32
PKT
-2,71
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
| 04.02.25 | UBS Hold | Deutsche Bank AG | |
| 04.02.25 | UBS Overweight | JP Morgan Chase & Co. | |
| 04.02.25 | Novartis Buy | Deutsche Bank AG | |
| 04.02.25 | UBS Outperform | RBC Capital Markets | |
| 04.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
| 03.02.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 03.02.25 | Novartis Hold | Deutsche Bank AG | |
| 03.02.25 | Novartis Kaufen | DZ BANK | |
| 03.02.25 | Nestlé Neutral | UBS AG | |
| 03.02.25 | Novartis Buy | UBS AG | |
| 31.01.25 | Roche Sell | Deutsche Bank AG | |
| 31.01.25 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 31.01.25 | Novartis Buy | UBS AG | |
| 31.01.25 | ABB (Asea Brown Boveri) Sell | Deutsche Bank AG | |
| 31.01.25 | Roche Neutral | UBS AG | |
| 31.01.25 | UBS Overweight | JP Morgan Chase & Co. | |
| 31.01.25 | Novartis Outperform | Bernstein Research | |
| 31.01.25 | Novartis Hold | Jefferies & Company Inc. | |
| 31.01.25 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
| 30.01.25 | Roche Outperform | Bernstein Research | |
| 30.01.25 | ABB (Asea Brown Boveri) Underperform | Bernstein Research | |
| 30.01.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 30.01.25 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
| 30.01.25 | Roche Neutral | UBS AG | |
| 30.01.25 | Roche Sell | Goldman Sachs Group Inc. | |
| 30.01.25 | ABB (Asea Brown Boveri) Neutral | Goldman Sachs Group Inc. | |
| 30.01.25 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 29.01.25 | Swiss Re Neutral | Goldman Sachs Group Inc. | |
| 29.01.25 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
| 29.01.25 | Swiss Re Buy | UBS AG | |
| 28.01.25 | ABB (Asea Brown Boveri) Underperform | Bernstein Research | |
| 28.01.25 | Givaudan Neutral | UBS AG | |
| 28.01.25 | Swiss Re Equal Weight | Barclays Capital | |
| 28.01.25 | Givaudan Buy | Goldman Sachs Group Inc. | |
| 28.01.25 | UBS Overweight | JP Morgan Chase & Co. | |
| 28.01.25 | Roche Neutral | UBS AG | |
| 27.01.25 | Novartis Buy | UBS AG | |
| 27.01.25 | Givaudan Add | Baader Bank | |
| 27.01.25 | Givaudan Add | Baader Bank |